WP3 - Severe Autoimmune Diabetes (SAID) - mechanisms & pathways
WP leaders
Åke Lernmark and Annelie Carlsson
Objectives
- To explore the influence of SAID heterogeneity on disease outcome
- To identify targetable mechanisms and pathways underlying initiation and progression of SAID
- To identify predictive biomarkers for the development of other concomitant autoimmune disease
Press releases
- International diabetes study receives SEK 40 million to continue (NIH/TEDDY): https://www.lunduniversity.lu.se/article/international-diabetes-study-receives-sek-40-million-continue
Publications
- Andersson Svärd A et al, DiPiS study group. Decreased HLA-DQ expression on peripheral blood cells in children with varying number of beta cell autoantibodies. J Transl Autoimmun 2020 https://pubmed.ncbi.nlm.nih.gov/32743532/
- Lind A et al. Screening for autoantibody targets in post-vaccination narcolepsy using proteome arrays. Scand J Immunol. 2020 https://pubmed.ncbi.nlm.nih.gov/32056243/
- Wallenius M et al. Autoantibodies in Pandemrix®-induced narcolepsy: Nine candidate autoantigens fail the conformational autoantibody test. Autoimmunity. 2019 https://pubmed.ncbi.nlm.nih.gov/31328572/
DiaUnion, the Medicon Valley Center for diabetes, autoimmunity and prevention
- Started in winter 2020, will run for 2.5 years
- Funded by the European Regional Development Fund
- Partners are Lund University, Steno Diabetes Center Copenhagen, Medicon Valley Alliance, The Capital Region of Denmark and Region Skåne
- https://mva.org/projects/diaunion/